Latest News

• Investigational Drug Tinostamustine to be Included in GBM AGILE Clinical Trial for Glioblastoma        

  The investigational drug tinostamustine (EDO-S101) will soon be added as a treatment arm in the Phase 2/3 GBM AGILE trial—a global, adaptive study designed to accelerate development of new therapies for glioblastoma. The GBM AGILE trial tests multiple therapies simultaneously against a shared control group and provides a potential pathway to FDA approval. Tinostamustine is a first-in-class compound that combines bifunctional alkylating activity with pan-HDAC inhibition, two mechanisms that may work together to attack glioblastoma cells more effectively. MD Anderson recently completed a small Phase 1 study of the drug in newly diagnosed, MGMT-unmethylated glioblastoma, but the results have not yet been published. In GBM AGILE, the drug will be evaluated in both newly diagnosed and recurrent glioblastoma patients. Activation of this trial arm is expected after regulatory submissions are approved, and we will be closely following for further updates.

  
  
• Dispersed Glioblastoma Cells Prove More Aggressive        

  A new study from researchers at Sylvester Comprehensive Cancer Center in Miami has shown that the spatial organization of glioblastoma (GBM) cells may play a key role in treatment resistance and clinical outcomes.

  Using single-cell spatial transcriptomics, the researchers showed that GBM cells organized in homotypic clusters maintain stable identities, while dispersed cells exhibit increased plasticity, shifting to alternative phenotypes and altering their surrounding microenvironment. This dispersed, glycolitic-plurimetabolic cell state was associated with significantly shorter survival.

  These findings raise the possibility that standard treatments—while essential—could inadvertently contribute to dispersal of GBM cells, potentially promoting a more therapy-resistant phenotype. While this hypothesis requires further validation, it is an important consideration for future therapy development.